European Partnership on One Health Antimicrobial Resistance
Landscape with river delta

The EUP OHAMR Joint Transnational Call 2027 is now open!

With an estimated total budget of €31 million, the EUP OHAMR Joint Transnational Call 2027 – Understand, Model and Stop AMR Transmission brings together 37 funding organisations from 27 countries to support international research collaborations aimed at improving our understanding of antimicrobial resistance (AMR) transmission and developing effective strategies to prevent its emergence and spread across the One Health spectrum.

The call will focus on preventing the emergence and spread of antimicrobial resistance (AMR), one of the most pressing global health challenges affecting humans, animals and the environment. Although significant efforts have been made and new technologies have emerged, current approaches remain insufficient to reduce the burden of AMR. A deeper understanding of transmission dynamics is essential to strengthen prevention and control strategies.

The call is co-funded by the European Union.

graphic illustrating research funding

New interactive dashboard for project data visualisation

Explore AMR research investments through the EUP OHAMR interactive dashboard. Bringing together project and funding data from EUP OHAMR and the Joint Programming Initiative on Antimicrobial Resistance (JPIAMR), the dashboard offers new opportunities to identify trends, compare investments and uncover research gaps across the AMR landscape.

The dashboard brings together data from both EUP OHAMR- and JPIAMR-supported projects, enabling users to search, filter and compare investments across research priority areas, One Health settings, funding organisations, countries and other key parameters.

Through interactive visualisations, project and funding data are transformed into insights, making it easier to identify trends, funding patterns, research gaps and opportunities for collaboration across the AMR landscape. Results can be explored dynamically and downloaded in both CSV and PowerPoint formats, supporting further analysis and knowledge sharing.

By making AMR research investments more visible, transparent and actionable, the dashboard serves as a valuable resource for researchers, funders, policymakers and other stakeholders, helping to strengthen evidence-based decision-making and maximise the impact of investments in AMR research and innovation.

EUP OHAMR JTC 2026 visual. A petri dish combined with a green circle on a blue background.

Twenty-one projects recommended for funding within the EUP OHAMR JTC 2026

Twenty-one projects involving 113 partners from 30 different countries have been recommended for funding within the EUP OHAMR Joint Transnational Call (JTC) 2026 – Treatments and adherence to treatment protocols. The call is co-funded by the European Union and has a total budget of 27,2 million Euro.

The projects will work to improve treatment success in humans, animals and plants affected by bacterial or fungal infections. Through the development of new treatment approaches and measures to support adherence to treatment protocols, they aim to reduce the emergence and spread of antimicrobial resistance across the One Health spectrum. The projects focus on the following three call topics:

  • Identify and develop new combination treatments using existing or innovative antimicrobials or antimicrobial with adjunctive treatments to extend drug efficacy and combat resistance.
  • Develop tools and methods to improve adherence to treatment protocols.
  • Assess the impact of antimicrobials for veterinary and agricultural use on the risk of AMR transmission to humans and the environment to inform policies on the restriction of some antimicrobials for human use.
Portrait of Shahida Syed

One year on: Building EUP OHAMR together

One year ago, we gathered in Brussels to launch EUP OHAMR and and embark on an ambitious ten-year journey. As we mark our first anniversary, Shahida Syed, Head of the EUP OHAMR Secretariat, reflects on our first year, why partnership matters for AMR, and her hopes for what we can achieve together in the years ahead.

One year ago, on 22–23 September 2025, we gathered in Brussels for the kick-off of the European Partnership on One Health Antimicrobial Resistance (EUP OHAMR).

There was a real sense of both opportunity and responsibility in the room. We were launching a ten-year European Partnership bringing together organisations and countries around one of the most complex global health challenges we face today: antimicrobial resistance (AMR).

Twelve months later, it feels like the right moment to reflect not only on what we have done, but on what we are building together – and why it matters.

From establishing a Partnership to putting it into action

The first year of any major partnership is necessarily about building foundations. For EUP OHAMR, that has meant turning an ambitious programme on paper into a functioning international partnership.

Over the past year, we have established our governance and ways of working, launched our first Joint Transnational Call, held our first Annual Meeting, established our scientific and strategic advisory structures, begun the development of our Stakeholder Forum, and advanced activities spanning research funding, capacity strengthening, data, policy, communication, innovation and impact.

We have also welcomed two new partners and strengthened connections with organisations and initiatives across the wider AMR, One Health and research and innovation ecosystem in Europe and internationally.

Behind these milestones has been a great deal of work, including navigating different organisations, national systems, priorities and working cultures. Perhaps my strongest reflection from this first year is that a partnership is not simply created through agreements or governance structures. It has to be built continuously through relationships, trust, shared purpose and, sometimes, compromise. It is on these foundations that we now build. The real measure of EUP OHAMR will be what this Partnership enables over the coming decade.

Why partnership matters for AMR

AMR makes the limitations of working in silos particularly visible. This is precisely why tackling AMR through a One Health lens is a necessity.

Resistance moves between humans, animals and the environment. Its drivers span healthcare, food systems, agriculture, veterinary medicine and environmental systems. Addressing it requires expertise ranging from microbiology and clinical research to social sciences, economics, implementation science, policy and innovation.

The same is true geographically. AMR does not respect borders, and addressing the research questions and developing the solutions needed requires collaboration across countries.

This is where EUP OHAMR has an important role.

By bringing together research funders, ministries, public authorities, researchers, policymakers and stakeholders over ten years, we have an opportunity to align national and shared priorities, coordinate investment, sustain commitment to AMR, build capacity, connect knowledge across sectors and countries, and strengthen the pathways through which research contributes to policy, practice and innovation.

That ability to take a long-term view is one of the Partnership’s greatest strengths, as addressing AMR requires sustained action over time.

Research must ultimately contribute to change

Another reflection from this first year is that our ambition must be both to support excellent research and to strengthen the pathways through which that research translates into impact.

We need to think from the outset about how knowledge can be used and what is needed to move from evidence to impact. This means reinforcing the science-policy interface, connecting researchers with policymakers, practitioners, innovators, patients and other end-users, and supporting implementation, innovation and the effective use and reuse of research data.

That perspective also needs to extend beyond Europe. AMR is inherently a global challenge, and EUP OHAMR sits within a much wider research and innovation ecosystem. We have an important opportunity to develop meaningful international connections, learn from different contexts and approaches, and ensure that our work both contributes to and benefits from the wider global AMR response.

Ultimately, we need to ensure that the research we support is connected to the needs of society and can contribute to meaningful and lasting change.

From foundations to delivery

Our first year has largely been about establishment and mobilisation. The coming years must increasingly be about delivery and connection.

As we move into this next phase, our focus shifts to delivering on our shared ambitions, learning and adapting as we go, and demonstrating the value of sustained collaboration on AMR.

We have an opportunity to establish EUP OHAMR as a central platform for One Health AMR research and innovation, but this also means remaining ambitious about what we can achieve together. Our joint research calls are fundamental to the Partnership, but its ten-year horizon gives us the opportunity to build on them: strengthening the wider AMR research ecosystem, creating connections that individual organisations, programmes or countries would struggle to create alone, and maximising the value and impact of our combined efforts.

A collective achievement – and a thank you

Perhaps most importantly, this anniversary is an opportunity to recognise the people behind the Partnership.

EUP OHAMR exists because organisations across many countries, together with the European Commission, have chosen to invest in AMR over the long term – not only funding, but also expertise, time and trust in a shared ambition. Much of the work involved in building a partnership happens behind the scenes, through the everyday commitment of people across our organisations who make this collaboration work.

I therefore want to extend a sincere thank you to all our partners and the many colleagues contributing across our work packages and activities, as well as to our colleagues at the European Commission for their continued support, engagement and dialogue. Your commitment is what makes this Partnership possible.

A particular thank you goes to our Coordination Unit and work package leaders, who have carried an enormous amount of responsibility during this first year and helped translate the Partnership’s ambitions into action.

I would also like to thank – and welcome – the members of our Strategic Board, Scientific Advisory Board, External Ethics Advisory Board and Stakeholder Forum, as well as the many organisations and individuals engaging with us externally. Their perspectives will be essential in ensuring that our work remains scientifically strong, strategically relevant and connected to societal needs.

Finally, a very personal thank you to the EUP OHAMR Secretariat at the Swedish Research Council. Establishing a new European Partnership while simultaneously beginning to deliver it has required flexibility, persistence and an extraordinary amount of work. I am immensely grateful for the commitment of the team, and it is a real privilege to work alongside you.

Looking ahead

When we met in Brussels a year ago, EUP OHAMR was at the beginning of a ten-year journey.

One year later, we are a growing community with a shared strategic direction and an increasingly clear sense of what we can achieve together.

There is still a great deal ahead of us. We will continue to learn and adapt, and undoubtedly encounter new challenges along the way. That is part of building something of this scale and ambition.

But there is also enormous opportunity.

The first year was about creating the Partnership.

The years ahead are about what we can achieve through it.

Groupe picture EUP OHAMR General Assembly

The EUP OHAMR General Assembly at the kick-off in Brussels 2025.

World map with EUP OHAMR countries marked with green. The countries are mentioned under the heading participating organisations on this page.

Two new partners join EUP OHAMR

We are very pleased to welcome both the Global Antimicrobial Resistance Research and Development Hub (Global AMR R&D Hub) and the Italian National Institute of Health (ISS) as new partners in the EUP OHAMR.

The addition of these organisations marks an important step in strengthening the Partnership’s expertise and international collaboration. Together, they bring extensive experience in AMR research, strategic coordination, evidence generation, and policy support, reinforcing EUP OHAMR’s mission to accelerate research and innovation through a One Health approach.

Shahida Syed, Head of Secretariat, EUP OHAMR, said:

“We are delighted to welcome both the Global AMR R&D Hub and ISS to the Partnership. Their expertise, international reach and commitment to the One Health approach will strengthen our collective efforts and enhance our ability to coordinate impactful research and innovation to tackle AMR. We look forward to working together to deliver lasting benefits for Europe and beyond.”

Lesley Ann Ogilvie, Director, Global AMR R&D Hub, said:

“AMR requires every one of us, across sectors and across nations, to bring our energy, our resources, and our commitment to building a safer, healthier world. That is why One Health AMR is more than a slogan to us—it is a guiding principle.

It is with great enthusiasm and a deep sense of honour that we join the EUP OHAMR. The Partnership’s mission to strengthen One Health research and innovation will be critical not only for Europe, but globally. We look forward to contributing the Hub’s data, insights, and expertise, and to working alongside our partners to advance our shared mission of tackling AMR through a truly One Health approach.”

Global AMR R&D Hub

The Global Antimicrobial Resistance (AMR) Research and Development (R&D) Hub is a partnership of countries, non-governmental donor organisations and intergovernmental organisations to address challenges and improve coordination and collaboration in global AMR R&D using a One Health approach.

The Hub supports governments and funders by mapping global AMR R&D investments, identifying research gaps and overlaps, and helping align funding priorities and strategies. Its Dynamic Dashboard is widely recognized as the world’s most comprehensive database of public and philanthropic AMR R&D investments. The Global AMR R&D Hub is funded by the German government and is administratively and legally hosted by the German Center for Infection Research (Deutsches Zentrum für Infektionsforschung e.V. – DZIF).

The Global AMR R&D Hub will be contributing to the EUP OHAMR Work Package 2, International Strategy Alignment and Collaboration in AMR, and Work Package 6, Knowledge valorisation to support exchange, transfer and uptake of research and innovation outcomes by end-users.

Learn more about the Global AMR R&D Hub (globalamrhub.org)

Italian National Institute of Health

The Italian National Institute of Health (Istituto Superiore di Sanità, ISS) is Italy’s leading biomedical and public health research institution and the main technical-scientific body of the National Health Service (Servizio Sanitario Nazionale, SSN). Operating under the supervision of the Ministry of Health, ISS provides scientific evidence, research and technical expertise to support public health policy and practice. Its work spans a broad range of health priorities, including AMR, infectious diseases, cancer, chronic and neurodegenerative diseases, rare diseases, and health promotion.

ISS will assume the official role of Leader of EUP OHAMR Work Package 4, Strengthening Capacity for Sustainable Antimicrobial Resistance Research, taking over from the Italian Ministry of Health. This change reflects an update in institutional affiliation, while ensuring continuity in leadership, as the same Work Package Leader will continue to guide WP4 and its activities.

Learn more about the Italian National Institute of Health (iss.it)

Webinar promotional picture

Success for EUP OHAMR – MSCA PF matchmaking webinar

On 25 June, the EUP OHAMR hosted the webinar "Building capacity in One Health Antimicrobial Resistance through Marie Skłodowska-Curie Actions Postdoctoral Fellowships (MSCA PF)."

The webinar brought together researchers, representatives of the European Commission, members of the EUP OHAMR, leading AMR research institutions, and Marie Sklodowska – Curie Actions (MSCA) Postdoctoral Fellows. It offered a valuable opportunity to learn more about MSCA Postdoctoral Fellowships and other funding opportunities, connect with potential host institutions, explore collaboration within the EUP OHAMR Partnership, gain first-hand insights from successful fellows, and establish new international research connections.

The event attracted nearly 100 participants from 82 countries worldwide, with particularly strong participation from low- and middle-income countries (LMICs) and Widening countries, highlighting the global interest in antimicrobial resistance research and international collaboration.

The webinar was organised within the framework of the European Partnership on One Health Antimicrobial Resistance (EUP OHAMR) with the support of the National Agency for Research and Development of the Republic of Moldova (NARD).

One Health Festival event image

One Health Festival webinar recording now available

During the One Health Festival, EUP OHAMR – together with the International Society for Infectious Diseases, ICARS, and the European Partnership on Animal Health and Welfare (EUP AH&W) – organised a webinar highlighting the importance of a One Health approach to tackling antimicrobial resistance.

Key themes included collaboration, surveillance, diagnostics, biosecurity, and vaccination, all under the shared message: Why One Health is your health.

Graphic illustrating the One Health concept

Engagement in global events: Spring highlights

In March and April, we actively engaged in a range of high‑profile global events, strengthening our visibility, networks, and strategic alignment on antimicrobial resistance (AMR) and One Health.

Inaugural Africa Fungal Disease Summit

2-3 March, Addis Ababa, Ethiopia. This landmark event convened over 100 high-level participants – policymakers, researchers, public health experts, donors, civil society and private sector partners – to catalyse Africa-led action on the rising burden of fungal infections and antifungal resistance.

The EUP OHAMR contributed to the panel Building research capability in LMICs: Lessons and Partnerships.

The event was organised by the Global Action for Fungal Infections (GAFFI) in collaboration with the Africa Centres for Disease Control and Prevention (Africa CDC).

First Americas Regional Meeting on Antimicrobial Resistance

Betsy Trainor - CARB-X, Lesley Ogillve - Global AMR R&D Hub, and Shawon Lahiri - EUP OHAMR, in a panel discussion.

Betsy Trainor – CARB-X, Lesley Ogillve – Global AMR R&D Hub, and Shawon Lahiri – EUP OHAMR, in a panel discussion.

23-27 March, Brasilia, Brazil. Policymakers, researchers, and practitioners from across Latin America and the Caribbean gathered to advance a shared agenda on AMR, grounded in a One Health approach. 

The meeting was organised by Brazil’s Ministry of Health (Ministério da Saúde) and other national, regional, and international organisations. It provided a space for regional dialogue and collaboration, with a shared focus on accelerating action on AMR through a One Health approach.

The EUP OHAMR supported the event and presented the partnership’s goals, highlighting the value of transnational collaboration and One Health approach in a panel discussion.

Health Partnership Day

17 March, Brussels, Belgium. Following our participation in the first Health Partnership Day in October last year, we had the opportunity to present the Partnership at this year’s second Health Partnership Day. Hosted once again by DG RTD, this informal workshop brought together Programme Committee members from the Cluster 1 “Health” configuration, along with invited experts from Member States and Associated Countries, to discuss the eight Health Co-Funded Partnerships.

We were pleased to present alongside the recently launched European Partnership on Pandemic Preparedness (BeReady) and the European Partnership for Brain Health. The event provided a valuable opportunity to connect with fellow coordinators of the Health Co-Funded Partnerships and with national experts, while exchanging views on how to further strengthen the implementation and impact of Horizon Europe Co-Funded Partnerships.

One Health Expert Symposium

19 March, Brussels, Belgium. We had the pleasure of presenting the Partnership at a One Health Expert Symposium organised by the British Embassy in Brussels, where we shared perspectives on building a truly collaborative One Health research community at the European level. 

The event brought together leading UK and European stakeholders to strengthen collaboration across critical cross-disciplinary areas. Opened by Professor Dame Sally Davies, the UK Special Envoy on AMR, we took part in the panel discussion on opportunities for collaboration within the One Health research community. We were pleased to contribute to the discussion and engage in the rich exchanges that followed on the operationalisation of the One Health approach, highlighting both the challenges and the opportunities ahead.

Civil Society as a Driving Force in the Global AMR Response

31 March, Brussels, Belgium. The WHO Civil Society Task Force on AMR presented their priorities and workstreams, followed by a panel discussion on ways to connect across interests and contexts with the aim of unlocking the unique values brought by civil society engagement. The seminar was co-arranged by EUP OHAMR partner organisation EPHA and the European Economic and Social Committee.

ESCMID GLOBAL 2026

Shahida Syed, EUP OHAMR, at the AMR in Action II event.

Shahida Syed, EUP OHAMR, at the AMR in Action II event.

19 April, Munich, Germany. We were pleased to co-host the ESCMID Global 2026 side-event AMR in Action II alongside ICARS, and the Global AMR R&D Hub. The event brought powerful case studies on AMR diagnostics – showing both their impact and the challenge of scaling uptake beyond developing cheaper tests toward redefining their value in AMR stewardship.

Participants at the EUP OHAMR Annual Meeting 2026

Successful EUP OHAMR Annual Meeting 2026 in Vienna

During four intensive meeting days this week, the first EUP OHAMR Annual Meeting brought together members of the Partnership, policymakers, and researchers from across Europe and beyond to discuss the Partnership’s ongoing work and future priorities. The meeting included the second in-person General Assembly, as well as several side meetings held in parallel.

Grounded in the cross-cutting themes of the EUP OHAMR Strategic Research and Innovation Agenda (SRIA), the first part of the General Assembly focused on the role of social sciences, AMR as a global challenge, and how implementation science and innovation can drive impact. The session featured presentations from members of the EUP OHAMR Scientific Advisory Board (SAB), followed by a panel discussion exploring barriers and opportunities, and underscoring the importance of integrating multiple perspectives in AMR research.

Panel members on the stage at the EUP OHAMR Annual Meeting.

Panel discussion at the General Assembly. From left: Ulrica Dohnhammar, EUP OHAMR Secretariat; Mohamed Elhadidy, SAB member; Fiona Walsh, SAB member; Jaap Wagenaar, SAB Chair; Nina Langeland, SAB Vice-Chair.

Photo: EUP OHAMR Secretrariat

During the Annual Meeting, the Scientific Advisory Board held its first in‑person meeting, and the newly established Strategic Board convened for a hybrid kick‑off meeting.

Several of the Partnership’s Work packages also took the opportunity to meet and discuss upcoming activities, and two different workshops were organised during the week:

  • WP4 Workshop on Capacity building
  • WP5 Workshop: Expert Consultation Session on the emerging Research Data Management framework

The EUP OHAMR Annual Meeting 2026 in Vienna was kindly hosted by the Austrian Agency for Health and Food Safety (AGES).

Jaap Wagenar and Nina Langeland

First Scientific Advisory Board appointed!

We are pleased to introduce the first Scientific Advisory Board (SAB) of the EUP OHAMR.

The SAB brings together 16 international experts who will provide strategic advice to the Partnership on scientific, research, innovation, and policy-related matters across the full One Health spectrum.

Jaap Wagenar, SAB Chair: “The presence of the diverse disciplines in the SAB reflects well the One Health approach of the Partnership. Members are linked to numerous other networks making the SAB a well-informed and embedded group.”

Nina Langeland, SAB Vice-Chair: “I am thrilled to take part in the scientific advice on the needs and the research gaps on AMR in Europe. The broad and complementary expertise in the SAB will strengthen our team.”

The SAB is appointed for a three-year term.